CIMZIA® (certolizumab pegol) can make a difference by improving skin manifestations in PsA patients

  • Primary efficacy measure was ACR20 response at week 12 for RAPID-PsA; ACR20 response at week 12 was 58% for CIMZIA vs 24% for placebo (P<0.001)1,10
  • PASI75 response rate at week 24 in patients with baseline psoriatic skin involvement ≥3% body surface area (62% of overall study population) was a key secondary endpoint
  • Treatment with CIMZIA resulted in improvement in skin manifestations in patients with PsA1,10

CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis.

Important Safety Information

  • Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (e.g. corticosteroids or methotrexate) may be at a greater risk of infection.
  • Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers, including children, adolescents, and young adults. Acute and chronic cases of leukemia have also been reported. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including CIMZIA. Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-antagonists, including CIMZIA. Periodic skin examinations are recommended for all patients, particularly those with risk factors for skin cancer.
  • Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus in patients who are chronic carriers of the virus. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.